Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B

06 Mar 2018

• By Deanna Kamienski, Beth Allan, and Maureen Riordan

Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in February 2018.

Antibiotics developer ABAC Therapeutics raised €16m ($19.8m) in its Series A financing led by Pontifax, which was joined by...